The GnRH antagonists currently used in clinical practice for prostate cancer treatment are derivatives of the natural decapeptide, where seven out of the ten residues are substituted with non‐proteinogenic amino acids (Figure 1). Here, GNRH1 is linked to prostate carcinoma.